First International Patient Treated with Fucaso® (Idecabtagene Vicleucel), a Domestically Developed CAR-T Therapy Priced at RMB 1.166 Million per Dose, Successfully Discharged from Shanghai Jiahui International Hospital
IASO Biotechnology
Cancer Treatment New Drug Developer
IASO Bio's Partner, Shanghai Jiahui International Hospital, Administers First Dose of Fokasol®(IASO Bio's Idecabtagene Vicleucel Injection) CAR-T TherapyForeign Multiple Myeloma Patient Discharged Smoothly Within Two Weeks After Completing Treatment。
This patient, from New Zealand, was diagnosed with multiple myeloma in 2008. Despite undergoing various treatments including chemotherapy, immunotherapy, targeted therapy, and autologous stem cell transplantation, he unfortunately relapsed again in 2022, accompanied by severe pain and bone damage. After consultation with Dr. Hua Li and Dr. Lili Zhou from the hematology team at Jiahui International Cancer Center, the patient decided to undergo CAR-T cell immunotherapy at Jiahui International Hospital. The entire treatment process went smoothly, and the patient was discharged within two weeks of treatment. Jiahui International Hospital boasts world-class facilities and comprehensive cancer treatment capabilities, and currently, several overseas patients with multiple myeloma have come to Jiahui International Hospital for treatment with Fokosu.®Treatment.
BlessingCanSu®Is the world's first approved fully human CAR-T product. Since its launch in China, IASO Bio has reached strategic cooperation with multiple international hospitals in China to jointly create an international CAR-T treatment center serving patients worldwide. Well-known international medical institutions have abundant medical resources and extensive channel networks, and their participation will accelerate Fokas.®Benefiting more overseas patients. Currently, multiple overseas patients have already benefited, showcasing the strength and potential of China's innovative drug development. IASO Bio will continue to focus on internationally synchronized and leading treatment concepts, drugs, and technologies, further advancing the long-term sustainable development of the CAR-T international diagnosis and treatment platform, bringing hope of a cure to multiple myeloma patients both in China and abroad!
About IASO Bio
E.N.D
Previous article recommendations:
CDE Releases "Technical Guidelines for Pharmaceutical Research and Evaluation of Clinical Trial Applications for In Vivo Gene Therapy Products Using Recombinant Adeno-Associated Virus Vectors"
Hengrui Medicine Subsidiary Submits First Gene Therapy Product
CDE Releases "Technical Guiding Principles for Non-Clinical Research of Human Stem Cell Products"
CDE Releases "Technical Guidelines for Clinical Trials of Gene Therapy Products for Rare Diseases"
CRISPR/Cas9 Gene Editing Therapy Receives FDA Approval for Treating β-Thalassemia
The Top Ten Advances in China's Pharmaceutical and Biotechnology in 2023 Revealed
WuXi Biologics: Sherry Gu to Serve as Chief Technology Officer and Executive Vice President
Review of 40 Global Stem Cell Therapy Companies and Their Technology Pipelines
Further Optimization of Small Nucleic Acid Drugs Can Reduce Production Costs by 60%
Nuo'en Gene Receives Tens of Millions of Yuan in Strategic Investment
$200 Million in Sales, the First DMD AAV Gene Therapy Drug Exceeds Expectations by a Wide Margin
CAR-T Drug Launches Pay-for-Performance Plan, Offering Up to 600,000 Yuan Refund
The Real "Bottleneck" in China's Biomedical Industry
$4.165 Billion!舶望制药Authorizes Novartis for Multiple RNAi Therapies
First Exosome Anti-Aging Stock Goes Public, Market Value Exceeds 490 Million Yuan
Disclaimer: The content is sourced from IASO Bio's official WeChat account. This article aims to share knowledge, and all content is for reference only and does not constitute any advice.